• Login
    View Item 
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Bio-Medical Sciences (Bio-Medical)
    • School of Bio-Medical Sciences (Bio-Medical) Collections
    • View Item
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Bio-Medical Sciences (Bio-Medical)
    • School of Bio-Medical Sciences (Bio-Medical) Collections
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Post-market quality of Rifampicin containing fixed-dose combinations of anti-tuberculosis drugs in Kampala, Uganda

    Thumbnail
    View/Open
    Masters Thesis (1.020Mb)
    Abstract (93.76Kb)
    Date
    2010-08
    Author
    Ocan, Moses
    Metadata
    Show full item record
    Abstract
    Background: Tuberculosis (TB) is an important curable infectious disease in Uganda; its treatment however is facing a challenge of increasing drug resistance. Although Rifampicin containing Fixed-Dose Combination (R-FDC) drugs are a mainstay in TB treatment, about 1/5 are reportedly substandard in the global drug market. Objective" To determine the post-market quality of R-FDC anti-TB drugs in Kampala, Uganda. Method: Eight private and five public pharmacies in Kampala were randomly selected, and the drug samples purchased or obtained as gifts respectively. Drug quality was assessed using visual inspection, weight uniformity, dissolution, and HPLC drug assay. Results: This study shows that 33.3% of R-FDC anti-TB drugs analyzed for drug assay contain rifampicin content outside the recommended compendial limits of 90-110% (U.S.P). Six batches of R-FDC anti-TB drugs were easily purchased without prescription from private pharmacies of Kampala city. This study found that 42.9% of the samples analyzed were not found in the National human drug register. All the drug samples passed visual/physical inspection and weight uniformity tests with all the samples having less than 5.0% relative standard deviation. All the FDC samples tested for rifampicin dissolution passed the test with all releasing more than 80.0% of rifampicin into solution in 45 minutes. Conclusion: Rifampicin containing FDC anti-TB drugs whose rifampicin content does not conform to the recommended pharmacopoeial standards exist in Kampala city, Uganda drug market.
    URI
    http://hdl.handle.net/10570/2918
    Collections
    • School of Bio-Medical Sciences (Bio-Medical) Collections

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of Mak IRCommunities & CollectionsTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy TypeThis CollectionTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy Type

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV